Selected Grants
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naive Essential Thrombocythemia Participants
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2024 - 2029A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naive myelofibrosis and moderate thrombocytopenia
Clinical TrialPrincipal Investigator · Awarded by Karyopharm Therapeutics · 2024 - 2029A Phase 2 Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis
Clinical TrialPrincipal Investigator · Awarded by Telios Pharma, Inc. · 2024 - 2029A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadeq
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2024 - 2029Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
Clinical TrialPrincipal Investigator · Awarded by Silence Therapeutics PLC · 2024 - 2029A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2023 - 2028Karyopharm: Phase 1/3 study of selinexor in combo with rux in treatment-naive patients with MF
Clinical TrialPrincipal Investigator · Awarded by Karyopharm Therapeutics · 2023 - 2028A22-301
Clinical TrialPrincipal Investigator · Awarded by PharmaEssentia USA Corporation · 2023 - 2028IMG-7289-CTP-203
Clinical TrialPrincipal Investigator · Awarded by Imago BioSciences · 2023 - 2028MCW:Txt Free Remission After Combo Therapy with Rux Plus Tyrosine Kinase Inhibition in CP-CML Who Relapsed after TKI Discontination
Clinical TrialPrincipal Investigator · Awarded by Medical College of Wisconsin · 2022 - 2027PTG-300-11
Clinical TrialPrincipal Investigator · Awarded by Protagonist Therapeutics Inc. · 2022 - 2027A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd Line Chronic Phase ? Chronic Myelogenous Leukemia (ASC2ESCALATE)
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2023 - 2027CGT9486-21-202
Clinical TrialPrincipal Investigator · Awarded by Cogent Biosciences, Inc · 2022 - 2027Protocol GRN163LMYF3001
Clinical TrialPrincipal Investigator · Awarded by Geron Corporation · 2022 - 2027Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2021 - 2026Randomized, Double-Blind, Placebo-Controlled Ph2 BLU-285 in Indolent and Smoldering Systemic
Clinical TrialPrincipal Investigator · Awarded by Blueprint Medicines Corporation · 2021 - 2026A Phase I Trial of Incorporating Natural Killer (K-NK) cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease After Tyrosine Kinase Inhibitor (TKI) Therapy
Clinical TrialPrincipal Investigator · Awarded by Kiadis Pharma · 2021 - 2026BBI Ph1 TP-3654 and Ruxolitinb in patients with Intermediate and High Risk Myelofibrosis
Clinical TrialPrincipal Investigator · Awarded by Sumitomo Dainippon Pharma Co. · 2020 - 2025Targeting beta-arrestins in myeloid malignancies
ResearchPrincipal Investigator · Awarded by Department of Defense · 2020 - 2024A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3K? Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2021 - 2024Phase 2 study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3ss) inhibitor, as a single agent or combined with Ruxolitinib, in patients with myelofibrosis
Clinical TrialPrincipal Investigator · Awarded by Actuate Therapeutics · 2020 - 2024A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia
Clinical TrialPrincipal Investigator · Awarded by Imago BioSciences · 2020 - 2023Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Clinical TrialPrincipal Investigator · Awarded by CTI Biopharma Corp. · 2020 - 2023COVID-19 Phase 3 Assess Efficacy of Ruxolitinib
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2020 - 2021A Phase 1b, multicenter, open-label dose escalation and expansion platform study of select combinations in adult patients with myelofibrosis
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2020 - 2021Targeting Beta-arrestins in myeloid malignancies
ResearchPrincipal Investigator · Awarded by American Society of Hematology · 2018 - 2020An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination with Low-Dose Ruxolitinib or Itacitinib Alone following Ruxolitinib in Subjects with Myelofibrosis
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2018 - 2020B-arrestin2 and the disease course of chronic myeloid leukemia (CML)
ResearchPI-Fellow · Awarded by American Society of Hematology · 2014 - 2015External Relationships
- AbbVie, Inc.
- Cogent Biosciences
- Dava Oncology
- Incyte Corporation
- Morphosys
- Novartis
- Sobi Pharmaceuticals
- Sumitomo Dainippon Pharma Oncology
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.